X

Drug Profile

TPI 1020

Alternative Names: NCX 1020; NO-budesonide; TPI-1020

Latest Information Update: 24 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NicOx
Developer NicOx; Topigen Pharmaceuticals
Class Antiasthmatics; Small molecules
Mechanism of Action Immunosuppressants; Nitric oxide donors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

14 Jan 2010 Discontinued - Phase-II for Asthma in Canada (Inhalation)
14 Jan 2010 Discontinued - Phase-II for Asthma in Europe (Inhalation)
16 Sep 2009 Preclinical pharmacodynamics data in Bronchial disorders presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com